Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
Suggested approach to the treatment of patients with newly-diagnosed... | Download Scientific Diagram
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma | NEJM
Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma. - Abstract - Europe PMC
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial - The Lancet Haematology
Carfilzomib, Lenalidomide, and Dexamethasone vs Quadruplet Regimen Among Transplant-Eligible Patients With Newly Diagnosed MM on Vimeo
Revlimid - NPS MedicineWise
Ixazomib in Combination with Cyclophosphamide/Dexamethasone or Lenalidomide/ Dexamethasone | Research To Practice
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
Tip Card: The VRd Regimen by International Myeloma Foundation - Issuu
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial -
When and How to Treat Relapsed Multiple Myeloma | American Society of Clinical Oncology Educational Book
Multiple Myeloma Treatment Option | REVLIMID® (lenalidomide)
Cancers | Free Full-Text | How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
Maintenance Therapy with Revlimid for Multiple Myelom
Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM | Research To Practice
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma - Lund - 2018 - Cancer Medicine - Wiley Online Library
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement | Leukemia
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma | Haematologica
Velcade/Revlimid/Dexamethasone New Standard for Newly Diagnosed Multiple Myeloma - CancerConnect
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
